Experimental combo therapy offers hope for Hard-to-Treat leukemia
NCT ID NCT05627232
First seen Nov 03, 2025 · Last updated Jun 12, 2026 · Updated 33 times
Summary
This early-phase study tests two new drug combinations for people whose acute myeloid leukemia (AML) has come back or not responded to prior treatment. In Part 1, participants receive tazemetostat plus standard chemotherapy (CPX-351). In Part 2, they get a pre-treatment drug (palbociclib) before the same chemotherapy. The main goal is to find safe doses and check for early signs that the drugs are working. About 24 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.